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Mouse monoclonal antibodies (mAbs) were raised against the major capsid protein, L1, of human papillomavirus type 16
(HPV16), produced in Escherichia coli with the expression plasmid pTrcL1. Epitope specificity could be assigned to 11 of
these 12 antibodies using a series of linear peptides and fusion proteins from HPV16. One mAb (MC53) recognized a novel
linear epitope that appears to be unique to the HPV16 genotype. A further 11 mAbs were characterized as recognizing novel
and previously defined linear and conformational epitopes shared among more than one HPV genotype. The apparently
genotype specific mAb could be useful for the development of diagnostic tests for vegetative virus infection in clinical
specimens. © 1998 Academic Press
INTRODUCTION
Human papillomavirus type 16 (HPV16) is one of more
than 70 different genotypes of papillomavirus known to
infect the skin and mucosa of man. Although about 30
HPV genotypes have been identified in the anogenital
tract, HPV16 is the most frequently detected in high-
grade cervical intraepithelial neoplasia and SCC,
(Koutsky and Kiviat, 1993; Munoz and Bosch, 1992). De-
tection and identification of HPV in clinical specimens
depends primarily on the use of DNA hybridization meth-
ods. Immunological detection methods based on the L1
capsid protein and specific for HPV16 might allow differ-
entiation between vegetative and latent infection and
would facilitate epidemiological studies on the natural
history and spread of infection.
Monoclonal antibodies (mAbs) have been produced
that recognize linear epitopes located within the central
position of the HPV16 L1 protein (Cason et al., 1989;
McLean et al., 1990) and conformational and linear
epitopes derived after immunization with L1 virus-like
particles (VLPs) (Christensen et al., 1996). However,
those that recognize linear L1 epitopes likely to be
present in denatured tissues either are genotype cross-
reactive or are of unknown genotype specificity. In this
paper, we describe the production of mAbs to an un-
fused, full-length L1 protein of HPV16 L1 and the char-
acterization of several linear epitopes, one of which is
likely to be type-specific for HPV16.
RESULTS
Reactivity of a panel of HPV16 L1-specific mAbs with
regions of the HPV16 L1 protein
A panel of monoclonal antibodies reactive with the L1
capsid protein of HPV16 was raised by immunizing a
mouse with PAGE-purified whole length recombinant
HPV16 L1, expressed in unfused form in Escherichia coli.
MAbs reactive with HPV16 L1 protein were further char-
acterized by immunoblot, using a series of recombinant
proteins incorporating distinct regions of HPV16 L1 (Ta-
ble 1, Fig. 1). Antibodies were also characterized by their
reactivity on immunoblot with a characteristic series of
degradation products of recombinant HPV16 L1 (Fig. 1)
resulting from activity of OmpT and other proteases
(Kelsall and Kulski, 1995). One mAb (MC12) reacted with
a recombinant polypeptide derived from the 172 amino-
terminal amino acids (aa’s) of HPV16 L1. Six mAbs (MC7,
-14, -18, -39, -40, and -53) reacted only with fusion pro-
teins including the 48 carboxyl-terminal aa’s. Four anti-
bodies (MC10, -15, -25, and -34) reacted with fusion
proteins which included aa’s 172–410 of the L1 molecule,
and each of these mAbs showed patterns of reactivity
with L1 degradation products distinct from the L1-spe-
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cific mAb CAMVIR1 that also reacts with this region of L1,
as exemplified for MC25 in Fig. 1, lane B10, and for
CAMVIR-1 in Fig. 1, lane D10. These 11 mAbs (MC7, -10,
-12, -14, -15, -18, -25, -39, -40, and -53) were therefore,
together with CAMVIR-1, selected for further analysis.
The antibodies were tested for reactivity against a series
of overlapping peptides corresponding to the entire pre-
dicted HPV16 L1 ORF. One antibody, MC25, reactive with
L1 fusion proteins comprising the central portion of
HPV16 L1 by immunoblot (Fig. 1) did not react with any of
the linear peptides. With this exception all mAbs mapped
to linear epitopes within the regions predicted from the
fusion protein studies, the 10 reactive mAbs reacting with
five distinct peptides (Table 2).
Reactivity of mAbs with recombinant L1 proteins from
other papillomaviruses
The reactivity of the panel of HPV16L1-specific mAbs
with the L1 proteins of HPV6b, -16, and -18, each ex-
pressed as authentic sequence recombinant proteins in
SF9 cells using L1 recombinant baculoviruses, and with
HPV18, HPV31, HPV33, and BPV1 L1 expressed in CV1
cells using a recombinant Vaccinia virus, was deter-
mined by immunoblot analysis (Fig. 2). Four mAbs rec-
ognized the peptide comprising aa’s 454–468 of HPV16.
Of these antibodies, two (MC18 and MC39) reacted
strongly with all other tested L1 proteins (Figs. 2B and
2G) and two (MC14 and MC40) did not react with HPV6
TABLE 1
Reactivity of a Series of HPV16 L1 Protein-Specific mAbs with Various Truncated and Complete HPV16 L1 Proteins
Recombinant
L1 plasmid
Encoded protein Reactivity with recombinant protein
Predicted
Mr
HPV16 L1 aa
sequence mAb 12
mAbs 10,
15, 25, 34
mAbs 7, 14, 39,
40, 53, 18 CAMVIR1
TrcL1 56 1–505 1 1 1 1
GEXL1 83 1–505 1 1 1 1
GEXL1TE 65 1–395 1 1 2 1
GEXL1TS 67 1–;410 1 1 2 1
HX-1 136 1–172 1 2 2 2
HX-2 154 172–505 2 1 1 1
HX-3 125 385–457 2 2 2 2
GEX 28 0 2 2 2 2
FIG. 1. Reactivity by immunoblot of HPV16L1-specific mAbs with a series of bacterial recombinant proteins containing HPV16L1 sequences. (A)
Reactivity with MC-12; (B) MC-25; (C) MC-40; (D) CAMVIR-1. In each panel recombinant proteins were expressed using bacterial expression vectors
as described in the legend to Fig. 1. Lanes: (1) pTrc HPV16 L1; (2) pGEXL1 uninduced; (3) pGEX L1 induced; (4) pGEXL1TE uninduced; (5) pGEXL1TE
induced; (6) pGEXL1TS uninduced; (7) pGEXL1TS induced; (8 and 9) pHX-1; (10) pHX-2; (11) pHX-3; (12) pGEX; (13) pEX-1. Molecular weight markers
(97.4, 69, 46, and 30 kDa) are indicated on the left in each panel.
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or HPV18 and were not tested against the other types. As
aa’s 454–468 of HPV16 L1 are relatively conserved
across PV genotypes (Table 3), these data allow the
prediction that mAbs 18 and 39 recognize an epitope
which is tolerant of substitutions to alanine at position
456 and that mAbs 14 and 40 recognize an epitope which
either is not tolerant of substitutions at position 456 or
includes the phenylalanine at position 461. MC15 reacted
strongly with all tested L1 sequences, suggesting that it
reacts with an epitope within the conserved sequence
306–313 (FNKPYWLQ), previously demonstrated anti-
genic by Cason et al. (1989). MC34 reacted with HPV31
and HPV33 L1 but not with other L1 proteins less closely
related to HPV16, suggesting that it reacted with the
epitope LYIKG from aa 274–278, another epitope defined
by Cason et al. (1989). MC10 also reacted with the linear
peptide from aa 264 to 278, but, in contrast to MC34,
reacted with HPV18 L1 and weakly with HPV6b L1 as
well as with HPV31 and HPV33 L1 protein. MAb MC12,
the only antibody recognizing a linear epitope in the
N-terminal 1
3
of the L1 protein reacted with HPV 31 L1, and
HPV 33 L1 but did not react with the L1 proteins of HPV
6b, HPV11, HPV18, or BPV-1 (Fig. 2D), indicating that the
recognized epitope is likely to lie within the conserved
sequence (KLDDTE) from aa 128 to 134 and is tolerant of
substitutions of the lysine residue. MC53 reacted with a
protein of apparent Mr corresponding to L1 only in the
HPV16 preparation (Fig. 2I). Reactivities at higher Mr
were demonstrated inconsistently with some rVV cell
lysates, including wt rV V and were presumed to repre-
sent cross reactivity with cellular components. This an-
tibody and MC7, which was not further characterized,
each recognized an epitope in a nonconserved region of
the nuclear localization signal of HPV16 L1. MC25, the
only antibody for which a linear epitope was not identi-
fied by peptide scanning, reacted strongly with all tested
L1 proteins, suggesting that it recognizes a conserved B
epitope, which from the pattern of reactivity with the
truncated L1 recombinant proteins should lie in the re-
gion from aa 172 to 395. The failure of this antibody to
react with linear overlapping peptides in repeated testing
suggests that this antibody recognizes a conformational
epitope: reactivity with L1 protein derivatives by immu-
noblot is not inconsistent with this conclusion as some
renaturing of proteins occurs when SDS is removed.
DISCUSSION
This study has confirmed two previously described B
epitopes within the HPV16 L1 sequence (E2, E3—Table
2) and defined at least five novel linear epitopes (E4–E7,
E9), one of which appears HPV16 specific (E7). Immuni-
zation of mice with a full-length L1 protein that was
purified from bacterial lysates by PAGE appears to be
comparable to immunization using disrupted viral parti-
cles. SDS- and heat-treated BPV1 particles produced
seven mAbs against 4 epitopes located between aa
position 198 and 420 and a polyclonal Ab against more
than 15 epitopes located between aa position 108 and
468 of the BPV1 L1 protein (Lim et al., 1990). By compar-
ison, we obtained 80 hybridomas that were reactive with
the L1 protein expressed by pTrcL1. Individual mAbs
raised against the recombinant L1 protein recognized 6
epitopes between aa position 124 and 488 of the L1
TABLE 2
Reactivity of the HPV16L1-Specific mAbs with HPV16 Synthetic Peptides and Other HPV Proteins
Antibody
Reactive HPV16 L1
peptidea
Location
on HPV16
L1 proteinb Reference
Reactivity with other HPV genotypes
Epitope
designationBPV1 HPV6 HPV11 HPV18 HPV31 HPV33
MC-12 KLDDTENASAYAANA 124–138 2 1/2 2 1/2 1 1 E4
MC-10 GTVGENVPDDLYIKG 264–278 2 1/2 2 1 1 1 E9
MC-34 GTVGENVPDDLYIKG 264–278 n.d.c 2 n.d. 2 1 1 E2
MC-15 QIFNKPYWLQRAQGH 304–318 1 1 1 1 1 1 E3
MC-14 FSADLDQFPLGRKFL 454–468 n.d. 2 n.d. 2 n.d. n.d. E5
MC-40 FSADLDQFPLGRKFL 454–468 n.d. 2 n.d. 2 n.d. n.d. E5
MC-18 FSADLDQFPLGRKFL 454–468 1 1 1 1 1 1 E6
MC-39 FSADLDQFPLGRKFL 454–468 1 1 1 1 1 1 E6
MC-7 KAKPKFTLGKRKATP 474–488 n.d. n.d. n.d. n.d. n.d. n.d. E7
MC-53 KAKPKFTLGKRKATP 474–488 2 2 2 2 2 2 E7
MC-25 None detected 2 1 1 1 1 1 1 E8
CAMVIR-1 GFGAMDF 203–209 McLean et al. (1990) 1 1 1 1 1 1 E1
8C4, 5A4, 1D6, ENVPDDLYIKGSGSTA 268–283 Cason et al. (1989)
3D1, 1C6 MVTSDAQIFNKPYWL 298–312 Cason et al. (1989)
a The sequence of the L1 peptide is given with single letter amino acid code. Bold residues are the minimal reactive epitopes.
b Relative to second methionine in the L1 ORF of HPV16.
c n.d., not determined.
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protein of HPV16. The greater diversity of epitopes rec-
ognized by mAbs in our study compared with previous
studies using fusion proteins suggests an advantage to
using a full-length protein in unfused form as an im-
munogen.
This study produced some antibodies with specificity
similar to those previously defined in HPV16. Epitope E2
lies within a region (aa 264–278) shown by Cason et al.
(1989) to contain a B epitope (DLYIKG), and four of five of
their L1 specific mAbs were directed to this epitope. As
DLY is found within HPV16, 31, and 33 but is not in
HPV6b, 18, or BPV1 (Table 3), and our antibody MC34
reacted only with L1 proteins with all three of these
residues, it is likely that this represents the minimal B
epitope. Another epitope defined in the present study
(E3) lies within the same region of L1 (aa’s 304–318) as
an epitope (FNKPYWL) previously shown reactive (Cason
et al., 1989) with one L1-specific mAb. As this epitope is
FIG. 2. Reactivity by immunoblot of HPV16L1-specific MAbs with L1 proteins of HPV6b, HPV11, HPV16, and BPV1 expressed as baculovirus
recombinants in SF9 cells and with HPV18, HPV31, and HPV33 L1 proteins expressed as recombinant VVs. Similar amounts of purified L1 protein of
HPV16, HPV6b, HPV11, and BPV1 were loaded as described in the legend to Fig. 2. Each panel represents reactivity with an individual antibody as
follows: (A) CAMVIR-1; (B) MC-18; (C) MC-10; (D) MC-12; (E) MC-15; (F) MC-25; (G) MC-39; (H) MC-34; and (I) MC-53. The position of the molecular
weight markers is indicated on the left. For each panel the lanes are: 1, wild type baculovirus cell lysate; 2, HPV16L1rBV; 3, HPV6L1rBV; 4, HPV11L1rBV;
5, BPV1L1 rBV; 6, wild type vaccinia virus cell lysate; 7, HPV18L1rV V; 8, HPV31 rV V; 9, HPV33 rV V.
TABLE 3
Comparison of Amino Acid Sequences of mAb-Reactive Peptides with Related Sequences of L1 Protein of Different Papillomavirus Types
Epitope region Peptide sequencea PV type
mAb reactivity
12 10 34 15 14 40 18 39 53
124–138 A.L.A..VNRKVTTQ BPV 2
.......SN..GG.P 6 6
.Y..V..SGG.GG.P 11 2
KLDDTENASAYAANA 16 1
......SSH.ATS.V 18 6
.F.....SNR..GGP 31 1
.F....TGNK.PGQP 33 1
264–278 .SEK.APTT.F.L.N BPV 2 2
.E...P...T..... 6 6 2
.T...P.....LV.. 11 2 2
GAVGENVPDDLYIKG 16 1 1
.TM.DT..QS..... 18 1 2
.T...S..T...... 31 1 1
.TL..A......... 33 1 1
304–318 ....R....F....M BPV 1
.L........K.... 6 1
.L........K.... 11 1
QIFNKPYWLQRAQGH 16 1
.L.......HK.... 18 1
........M...... 31 1
.L............. 33 1
454–468 L.L.........R.. BPV 1 1
..SE...Y....... 6 2 2 1 1
..SE........... 11 1 1
FSADLDQFPLGRKFL 16 1 1 1 1
..L....Y....... 18 2 2 1 1
............... 31 1 1
............... 33 1 1
474–488 STVR.RRISQKTSSK BPV 2
RGRSSIRT.VKRPAV 6 2
RGRTSART.IKRPAV 11 2
KAKPKFTLGKRKATP 16 1
RR..TIGPR..S.PS 18 2
R.R...KA...S.P. 31 2
.....LKRAAPTS.R 33 2
a The single letter amino acid code is used throughout—periods represent conserved residues.
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conserved across all tested PV L1 proteins and our
antibody MC15 was reactive with each of these, it is
probable that MC15 will share this specificity. Sequences
within E3 were also recognized by a mAb raised against
HPV33 L1 fusion protein that had been produced in E.
coli (Sapp et al., 1994). This sequence is highly con-
served (.90%) across most PV genotypes for which
sequence is available and thus antibodies of this spec-
ificity will likely detect most PV L1 capsid proteins after
denaturation.
Three of the novel B epitopes defined in this study
(E5–E7) are clustered within a conserved C-terminal re-
gion of the HPV L1 protein. The function of this region is
not known, but it is not essential for capsid formation.
One epitope (E7) lies within a nuclear localization se-
quence region of L1 (Zhou et al., 1991), which is not
conserved from PV to PV genotype, and the antibody
reactive with this epitope, MC53, was specific for HPV16
among the tested genotypes. Further analysis of 71 pre-
dicted L1 protein sequences from the EMBL database
showed no better match for the HPV16 sequence in this
region than the nonreactive HPV33 sequence, suggest-
ing that this epitope may be HPV16 specific. The ap-
parently conformational epitope (E8) is potentially of in-
terest as it is conserved across six quite divergent HPV
genotypes, and antibodies recognizing conformational
epitopes have potential as virus neutralizing antibodies
(Hines et al., 1994).
Interestingly, none of the epitopes defined in this pa-
per overlap with any of the series of seven linear
epitopes defined by the mAbs raised by Christensen et
al. (1996) using HPV16 L1 VLPs as immunogen, suggest-
ing that the epitopes presented by VLPs to the mouse
immune system are not seen as such when L1 is pre-
sented as a linear bacterial protein. Many of the B
epitopes recognized in the present series are conserved
across many PV genotypes, suggesting that there is little
immune selection pressure on these epitopes. This
could mean that these linear epitopes are neither pro-
duced nor presented in the course of natural infection, or
alternatively that an immune response to these epitopes
of PV L1 protein is not a determinant of the outcome of
exposure to PV infection.
MATERIALS AND METHODS
Vectors and expression of full-length or fragmented
L1 protein
The prokaryotic expression constructs containing
HPV16 sequence that were used in this study are shown
in Fig. 3. The 505 amino acids of the L1 coding sequence
(nts 5637–7154) of HPV16, starting from the second initi-
ation codon of the L1 ORF (Seedorf et al., 1985) were
expressed in an unfused form with the bacterial expres-
sion vector pTrcL1 (Kelsall and Kulski, 1995) and in a
fused form with bacterial expression vector pGEXL1
(Kelsall and Kulski, 1994). The bacterial expression plas-
mids pGEXL1TE and pGEXL1TS contained a truncated
L1 sequence with approximately 300 nts deleted from the
59 end of the stop codon by EcoRI or S1 nuclease
digestion, respectively, and expressed a protein with a
deletion of approximately 105 amino acids from the car-
boxy-terminal end. The plasmids pHX-1 and pHX-2 ex-
pressed the amino-terminal (1 to 172 aa) and carboxy-
terminal (172 to 505 aa) ends of the L1 protein, respec-
tively, fused with cro-b-galactosidase of the pEX vector
FIG. 3. Schematic representation of various prokaryotic expression constructs containing HPV16L1 sequence. For each, the expressed HPV16 L1
amino acids are followed by a designation given to the construct. The vector proteins, 26-kDa glutathione S-transferase (Sj26) and 117-kDa cro-b
galactosidase (cro-b-gal) are fused to the amino terminus of the L1 capsid protein and are represented in the diagram for pGEX and pHX vectors by
horizontal and vertical shading respectively.
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(Browne et al., 1988). The plasmid pHX-3 contained a
216-bp PstI fragment from the L1 ORF of HPV16 DNA (nts
6792–7008) that was inserted into the PstI site of the
bacterial expression vector pEX-1 to express a 72-aa
fragment of the L1 protein (amino acid position 385 to
457) fused with cro-b-galactosidase.
HPV6, HPV16, or HPV18 L1 proteins were produced
and purified as VLPs in insect cells (Sf9) (Fig. 4) after
infection with recombinant baculoviruses encoding
HPV6L1, HPV16L1, or HPV18L1 as previously described
(Park et al., 1993). BPV1 L1 VLPs were produced in CV-1
cells using a rVV as previously described (Zhou et al.,
1993). HPV18, HPV31, and HPV33 L1 proteins were
produced as lysates of cells infected with the appropri-
ate recombinant vaccinia virus. These recombinant vac-
cinia viruses were constructed by recombination of
pMJ601-L1 plasmids into the vaccinia virus vector using
methods described previously (Hagensee et al., 1993).
The L1 coding sequences were obtained by PCR cloning
using primers containing SalI and SmaI ends: HPV18,
59-TGGCTTGAATTCGTCGACAGATGGCTTTGTGGCG-
GCC-39 39-CGAAGCGAATTCCCCGGGTTACTTCCT-
GGCACGTACACG-59; HPV31, 59-TTGCTTGAATTCGTC-
GACATGTCTCTGTGGCGGCC-39, 39-CGAAGCGAAT-
TCCCCGGGTTACTTTTTAGTTTTTTTACG-59; HPV33,
59-TTGCTTGAATTCGTCGACAGATGTCCGTGTGGCG-
GCC-39, 39-CGAAGCGAATTCCCCGGGTTATTTTTTA-
ACCTTTTTGCG-59. The PCR products were cleaved and
ligated into similarly cleaved pMJ601 vector plasmid.
Virus was plaque purified three times; expression of L1
protein was confirmed by immunoblot with polyclonal
cross-reactive L1 sera and capsid formation was as-
sessed by electron microscopy (G. Wipf and D. A. Gal-
loway, unpublished results).
Production of mouse mAbs
The HPV16 L1 capsid protein expressed in E. coli
(JM101) with the plasmid pTrcL1 was separated from
bacterial proteins on 4–18% SDS–PAGE gradient gels
(Kelsall and Kulski, 1995), purified, quantitated, and used
to immunize BALB/c mice. The protein was highly pure
as judged by the presence of only a single band in a lane
of an SDS gel heavily overloaded with the purified L1
protein and stained with Coomassie blue R-250. BALB/c
mice were immunized three times with 10 mg protein in
Freund’s adjuvant. A single-cell suspension of splenic
lymphocytes was prepared from the highest responder
and fused with mouse myeloma cells X63 Ag8.653 at a
cell ratio of 3:5 in 50% polyethylene glycol (Mr 1000, BDH)
for 90 s and then diluted in RPMI medium containing 20%
fetal bovine serum and HAT (0.96 mM hypoxanthine, 0.16
mM thymidine, 0.36 mM aminopterin). The resultant hy-
brid cells were plated into 96-well microtiter plates (five
plates per spleen) containing spleen feeder cells. Eighty
hybridomas that secreted antibody against L1 protein
expressed by pTrcL1 were screened by Western immu-
noblotting using bacterial preparations of pTrcL1.
Immunoblotting
SDS–PAGE and immunoblotting for detection of re-
combinant L1 proteins that had been expressed in bac-
teria were performed as described previously (Kelsall
and Kulski, 1995). Immunoblots for detection of reactivity
with HPV6b, HPV11, HPV16, or HPV18 L1 proteins ex-
pressed by recombinant baculoviruses and BPV1,
HPV18, HPV31, and HPV33 L1 protein expressed using
rV V were essentially as described for the bacterial pro-
teins except that blots were blocked with 5% skim milk in
PBS at 4°C overnight, goat anti-mouse alkaline phos-
phatase was used as a detection conjugate (Promega),
and color development was with NBT-BCIP.
Peptides and linear epitope mapping
A series of 15-mer peptides, overlapping by five resi-
dues and spanning the deduced amino acid sequence of
HPV16 L1 protein, was used to screen mAbs by ELISA
essentially as described previously (Zhou et al., 1992). To
denote the position of the amino acids in the L1 protein,
the putative second initiation codon was designated
amino acid number 1.
Computer analysis of papillomavirus L1 protein
sequences
Peptide sequences recognized by the mAbs were
aligned with the L1 protein sequences and the var-
FIG. 4. Protein composition of purified L1 VLPs. L1 protein expressed
using recombinant baculovirus in Sf9 cells was purified as VLPs from
cell lysates by density gradient separation and dialysed against PBS
buffer. Approximately 1.5 mg of each L1 protein was separated by
SDS–PAGE and stained with Coomassie blue.
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ious HPV L1 protein sequences were aligned using
‘‘Megalign’’ sequence alignment software (DNAstar).
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